All posts by medical

NEUROSCIENCE ANTIBODIES AND ASSAYS Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 – The Daily…

Fort Collins, Colorado The NEUROSCIENCE ANTIBODIES AND ASSAYS Market is growing at a rapid pace and contributes significantly to the global economy in terms of turnover, growth rate, sales, market share and size. The NEUROSCIENCE ANTIBODIES AND ASSAYS Market Report is a comprehensive research paper that provides readers with valuable information to understand the basics of the NEUROSCIENCE ANTIBODIES AND ASSAYS Report. The report describes business strategies, market needs, dominant market players and a futuristic view of the market.

The report has been updated to reflect the most recent economic scenario and market size regarding the ongoing COVID-19 pandemic. The report looks at the growth outlook as well as current and futuristic earnings expectations in a post-COVID scenario. The report also covers changing market trends and dynamics as a result of the pandemic and provides an accurate analysis of the impact of the crisis on the market as a whole.

Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market to reach USD 5.1 billion by 2025. Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market valued approximately USD 2.1 billion in 2016 is anticipated to grow with a healthy growth rate of more than 10.3% over the forecast period 2017-2025.

Get a sample of the report @ https://reportsglobe.com/download-sample/?rid=4794

Industry NEUROSCIENCE ANTIBODIES AND ASSAYS Study provides an in-depth analysis of key market drivers, opportunities, challenges and their impact on market performance. The report also highlights technological advancements and product developments that drive market needs.

The report contains a detailed analysis of the major players in the market, as well as their business overview, expansion plans and strategies. Key players explored in the report include:

The report provides comprehensive analysis in an organized manner in the form of tables, graphs, charts, pictures and diagrams. Organized data paves the way for research and exploration of current and future market outlooks.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=4794

The report provides comprehensive data on the NEUROSCIENCE ANTIBODIES AND ASSAYS market and its trends to help the reader formulate solutions to accelerate business growth. The report provides a comprehensive overview of the economic scenario of the market, as well as its benefits and limitations.

The NEUROSCIENCE ANTIBODIES AND ASSAYS Market Report includes production chain analysis and value chain analysis to provide a comprehensive picture of the NEUROSCIENCE ANTIBODIES AND ASSAYS market. The research consists of market analysis and detailed analysis of application segments, product types, market size, growth rates, and current and emerging industry trends.

By Product :

By Technology:

By End User:

Request customization of the report @https://reportsglobe.com/need-customization/?rid=4794

The market is geographically spread across several key geographic regions and the report includes regional analysis as well as production, consumption, revenue and market share in these regions for the 2020-2027 forecast period. Regions include North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Radical Coverage of the NEUROSCIENCE ANTIBODIES AND ASSAYS Market:

Key Questions Addressed in the Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-neuroscience-antibodies-and-assays-market-size-study/

Thanks for reading our report. It is possible to adapt this report to the wishes of the customer. Contact us to learn more about the report and our team will make sure you create a report based on your needs.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

Read more here:
NEUROSCIENCE ANTIBODIES AND ASSAYS Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily...

STEM CELL BANKING Market Outlook, Recent Trends and Growth Forecast 2020-2026 – The Research Process

The NEUROSCIENCE ANTIBODIES AND ASSAYS market analysis report contributes a unique combination of market insights and qualitative analysis which later helps companies to achieve remarkable growth. As an advancement this report is generated by our NEUROSCIENCE ANTIBODIES AND ASSAYS market research professionals using latest research tools, technics and methodology.

The report provides insights on the following sections:

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/10139

Global NEUROSCIENCE ANTIBODIES AND ASSAYS industry profile provides top-line qualitative and quantifiable information including: NEUROSCIENCE ANTIBODIES AND ASSAYS market share, market size. The profile also contains descriptions of the foremost players including key financial metrics and analysis of competitive pressures within the NEUROSCIENCE ANTIBODIES AND ASSAYS market. Essential resource for top-line data and analysis covering the global NEUROSCIENCE ANTIBODIES AND ASSAYS market. Includes NEUROSCIENCE ANTIBODIES AND ASSAYS market size and segmentation data, textual and graphical analysis of NEUROSCIENCE ANTIBODIES AND ASSAYS market growth trends and leading companies.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/10139

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:

Some of the Highlights about Table of Content of NEUROSCIENCE ANTIBODIES AND ASSAYS Market

1 NEUROSCIENCE ANTIBODIES AND ASSAYS Market overview

2 Executive Summary

3 Market Drivers, Challenges and Trends

4 Marketing, Distributors and Customer

5 Key Players Analysis

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/10139

View original post here:
STEM CELL BANKING Market Outlook, Recent Trends and Growth Forecast 2020-2026 - The Research Process

Reasons Revealed for the Brain’s Elastic Sense of Time – Quanta Magazine

Our sense of time may be the scaffolding for all of our experience and behavior, but it is an unsteady and subjective one, expanding and contracting like an accordion. Emotions, music, events in our surroundings and shifts in our attention all have the power to speed time up for us or slow it down. When presented with images on a screen, we perceive angry faces as lasting longer than neutral ones, spiders as lasting longer than butterflies, and the color red as lasting longer than blue. The watched pot never boils, and time flies when were having fun.

Last month in Nature Neuroscience, a trio of researchers at the Weizmann Institute of Science in Israel presented some important new insights into what stretches and compresses our experience of time. They found evidence for a long-suspected connection between time perception and the mechanism that helps us learn through rewards and punishments. They also demonstrated that the perception of time is wedded to our brains constantly updated expectations about what will happen next.

Everyone knows the saying that time flies when youre having fun, said Sam Gershman, a cognitive neuroscientist at Harvard University who was not involved in the study. But the full story might be more nuanced: Time flies when youre having more fun than you expected.

Time doesnt mean just one thing to the brain. Different brain regions rely on varied neural mechanisms to track its passage, and themechanisms that govern our experience seem to change from one situation to the next.

But decades of research suggest that the neurotransmitter dopamine plays a critical role in how we perceive time. Dopamine has myriad effects on how much time we think has elapsed in a given period, and these effects may conflict confusingly. Some studies have found that increasing dopamine speeds up an animals internal clock, leading it to overestimate the passage of time; others have found that dopamine compresses events and makes them seem more fleeting; still others have uncovered both effects, depending on context.

Dopamines association with time perception is intriguing, in part because the neurotransmitter is better known for its function in reward and reinforcement learning processes. When we receive an unexpected reward, for instance in whats known as a prediction error we experience a rush of the chemical, which teaches us to continue pursuing that behavior in the future.

Its likely more than a coincidence that dopamine is so fundamental to both time perception and learning processes. Drugs like methamphetamine and neurological disorders like Parkinsons alter both processes and also involve changes in dopamine. And learning itself the association of a behavior with its outcome requires the linking of one event with another in time. Really, at the very core of reinforcement learning algorithms is information about time, said Joseph Paton, a neuroscientist at the Champalimaud Foundation in Portugal. (Paton was an investigator for the Simons Collaboration on the Global Brain, funded by the Simons Foundation, which also funds Quanta Magazine.)

But scientists have yet to disentangle just how and where reinforcement learning and time perception are integrated in the brain. Instead, the two fields have traditionally stayed quite separate, said Martin Wiener, a psychologist at George Mason University. No one has asked, How does reinforcement learning affect timing, or vice versa, if theyre both using the same neurotransmitter system?

The new Nature Neuroscience paper by Ido Toren, Kristoffer Aberg and Rony Paz examines that question more closely. Study participants saw two numbers flash on a screen, usually a zero followed by another zero. The second number was shown for a varying amount of time, and participants had to report which number lasted longer. But sometimes, randomly, a positive or negative integer was presented instead of that secondzero: If it was positive, participants were rewarded with money, but if it was negative, money was taken away as a penalty.

For the participants, the consequences lined up with shifts in the perceived duration of the second stimulus. When something unexpected but good happened a positive prediction error, as researchers called it the stimulus seemed to last longer. The unwelcome surprises of negative prediction errors made those experiences seem shorter. It basically tells us that our perception of time is going to be systematically biased by how surprised we are about outcomes, said Matthew Matell, a psychologist at Villanova University who was not involved in the study.

The team showed that this pattern held quantitatively, with greater prediction errors correlating with greater distortions of perceived time. A reinforcement learning model that they built was able to predict each subjects performance on the task. Brain scans of the study participantstracked this effect in a region called the putamen, which is involved in motor learning and other functions.

Although further experiments are needed to pin down the precise mechanism at hand (and the role of dopamine), the study has implications for models of both learning and time perception. Pavlovs slobbering dog learned that a bell meant food, and that the food would taste a certain way but also that the food was imminent. Yet that temporal component has usually been relegated to the periphery of reinforcement learning models. The objective timing of a reward has oftenbeen incorporated as a variable, but the subjective aspects of time perception that the new work emphasizes have not.

It might be time to start including some of that subjectivity. If humans stretch or contract their experience of time in response to signals, this might also alter their perceptions of how close or far apart certain actions and outcomes are which could in turn influence how quickly those associations are learned. Timing effects related to prediction errors also provide an extra characteristic that reinforcement learning models have to fulfill if theyre going to be an accurate representation of whats going on, said Bowen Fung, a former postdoctoral researcher at the California Institute of Technology who now works at an organization called the Behavioral Insights Team in Australia.

It challenges future modelers, or people who are trying to develop an understanding of the brain, to take into account how these two systems are interfacing, Matell said. Gershman and his doctoral student John Mikhael have been developing a learning model that incorporates these ideas, in which mental predictions are improved by adaptivelyadjustingthe flow of time in the brain.

But prediction errors arent the only factors that shape our perception of time. Take a study published last week in the Journal of Neuroscience: Participants who were repeatedly exposed to a brief stimulus tended to overestimate the duration of slightly longer time intervals. According to the researchers, thats probably because the neurons responsive to shorter durations became fatigued, giving neurons tuned to longer durations greater influence over how subsequent stimuli were perceived. (Similarly, after being repeatedly exposed to a long stimulus, the test subjects underestimated the duration of slightly shorter intervals.)

By changing the context of the stimulus presentation, we can actually manipulate how participants perceive those durations, said Masamichi Hayashi, a cognitive neuroscientist at the National Institute of Information and Communications Technology in Japan, who conducted the work with Richard Ivry of the University of California, Berkeley. Scans of brain activity suggested that an area in the right parietal lobe is responsible for this subjective experience of time.

Hayashi and Ivry focused on an entirely different brain region and mechanism than the Weizmann scientists did and yet both studies observed a similar bidirectional effect on time perception. On the one hand, this demonstrates just how distributed and diverse timekeeping processes are in the brain. But the right parietal lobe does have functional and anatomical connections to the putamen, Hayashi said, so perhaps the interactions of the two produce a more cohesive perception of time. Whatever broad rules and computations make those interactions (and others) possible may underlie our experience of time, but until they are pinpointed, scientists can only watch the clock or clocks in anticipation.

Read the original here:
Reasons Revealed for the Brain's Elastic Sense of Time - Quanta Magazine

The Brandeis alum whose research may lead to a COVID-19 vaccine – Brandeis University

Scientist Drew Weissman's research is the basis for several vaccines being developed to fight the pandemic.

It is no exaggeration to say that Drew Weissman '81, MS '81, is among a handful of scientists whose research may save the world from COVID-19.

Now his findings and the system he developed for delivering mRNA into cells underpin two of the most promising candidates for a coronavirus vaccine, one being developed by Pfizer and BioNTech and the other by Moderna.

Drew Weissman

Weissman, a professor of medicine at the Perelman School of Medicine at the University of Pennsylvania, is also working with the government of Thailand on a COVID-19 vaccine for the developing world. It is expected to be more affordable and easier-to-produce than the vaccines being created by drug companies.

A biochemistry major at Brandeis, Weissman worked in professor Gerald Fasmans lab.

"He definitely gave me insights on how to develop hypotheses how to think about them, how to develop new lines of research," said Weissman, who wrote his master's thesis on acetylation of DNA, part of the process of gene regulation.

Messenger molecules, mRNA transport instructions from DNA to the ribosomes in our cells for the production of proteins.

In a traditional chickenpox, polio, flu or rabies vaccine, a weakened or killed version of the virus is injected, fooling the immune system into fighting the disease.

But manufacturing a virus is a lot more expensive than synthesizing mRNA. And it isnt necessary to create an entirely new vaccine for each disease using mRNA since the mRNA can be reprogrammed to fight the target illness.

Many researchers gave up on mRNA, but Weissman and Karik persisted. "We were getting interesting results, so they just kept leading us on," Weissman said.

They replaced one of mRNAs four chemical building blocks, a nucleoside called uridine, with a slightly modified nucleoside called pseudouridine. This enabled the mRNA to skirt the body's immune system.

In the late 2010s came several more major breakthroughs. The researchers used mRNA to immunize mice against genital herpes (which is caused by the herpes simplex virus), influenza, Zika and HIV.

If it works, a COVID-19 mRNA vaccine will spur human cells to produce the spike-shaped protein found on SARS-CoV-2, the virus that causes the illness, and will trigger the immune system to produce protective antibodies.

Weissman is now focusing on an even more ambitious project developing a vaccine for all coronaviruses. Besides SARS-CoV-2, two other lethal varieties of coronavirus SARS and MERS have spread among humans in recent years.

Go here to see the original:
The Brandeis alum whose research may lead to a COVID-19 vaccine - Brandeis University

Immunology as The Ultimate Riddle A Conversation with an Immunologist – BioSpace

Immunology is one of the most complex fields of life science to study. Thousands of scientists utilize their expertise in biology to focus on autoimmune diseases, cancer, immunodeficiencies and other immune disorders to help patients and cure diseases. We recently interviewed Marianne Stanford, Ph.D., who serves as Vice President of Research and Development at IMV, Inc. Stanford shared her thoughts on the field and the career path of an immunologist. If you are interested in immunology, hearing from a leader in industry and academia is beneficial!

I was born and raised in Newfoundland, a small province on the eastern coast of Canada. Growing up, I always saw myself as someone keenly focused on science and yet the only career option I saw for myself was as a veterinarian. Once I entered university, I began to see the breadth of career paths you could do in science. I tried several, including working as a summer field biologist, and quickly learned that working in the field was not for me. That lead me to work in the lab. Fundamentally, looking back, Ive always been someone asking questions this fundamentally led me to be a scientist.

Immunology is the study of our immune system. The immune system is in some ways the ultimate riddle in some ways so simple and yet ridiculously complex. The job of the immune system is to determine what is self and protect it from invaders. But the way in which it does this is something we learn more about every day. For that reason, it is a great (and yet sometime very frustrating) field of study!

I think that whats really interesting about studying the immune system is that everyone feels that they have a good handle on what their immune system is and how it works. We understand that our body fights disease and that vaccines help protect us. However, once you begin to study the immune system in depth, you realize that there are so many things that we do not fully understand and that harnessing the immune system is incredibly difficult to do in the clinic.

There are a couple of really exciting new opportunities that have emerged in immunology in recent years. First and foremost, as our understanding of the checks and balances in the immune system have allowed us to advance new therapies that act directly on it to impact disease. The most obvious one is the advances of immunotherapy in cancer, whereby we manipulate and stimulate the immune system to help fight diseases like cancer. This has opened a huge opportunity to treat many diseases with our own immune system, hopefully being more effective with fewer side effects. The second has been the understanding of the microbiome, or how the microbes that make up our bodies have a direct impact on our immune system. This study may change how we think of this interaction and is very exciting to follow.

I think the opportunity to be on the cutting edge of new treatments for diseases like cancer are so gratifying. There are also many opportunities for collaboration and working with other great scientists on complex questions. This is an awesome way to work.

I think like any field, to be at your best you need to find the right opportunities for mentorship and training. Ive been very lucky to work with world-class scientists during my training and that has really allowed me to be successful.

Keep asking questions and never give up. Surround yourself with people who are passionate and as focused on mentorship as they are in science.

Porschia Parker-Griffin is a Certified Coach, Professional Resume Writer, and Founder of Fly High Coaching. (https://www.fly-highcoaching.com) She empowers ambitious professionals and motivated executives to add $10K on average to their salaries.

Marianne Stanford, PhD. is Vice President of Research and Development at IMV Inc., overseeing all preclinical research activities and clinical immunology assessment of cancer immunotherapies and infectious disease vaccines. In addition, she serves as an Adjunct Professor in Microbiology and Immunology at Dalhousie University. Dr. Stanford received her BSc and MSc from Memorial University of Newfoundland and her PhD from Dalhousie University.

Read more:
Immunology as The Ultimate Riddle A Conversation with an Immunologist - BioSpace

Immunology Market ? What Factors Will Drive The Market In Upcoming Years And How It Is Going To Impact On Global Industry | (2020-2026) – The Daily…

DataIntelo has published a latest market research report on Global Immunology Market. The global report is prepared in collaboration with the leading industry experts and dedicated research analyst team to provide an enterprise with in-depth market insights and help them to take crucial business decisions. This report covers current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market.

The published report explains about the current supply and demand scenario and presents the future outlook of the market in a detailed manner. DataIntelo has applied a robust market research methodology to bestow the new entrants and emerging players with 360 wide-view analysis on the latest advancements and their impacts on the market. It has congregated massive amount of data on the key segments of the market in an easy to understand format. The research report has laid out the numbers and figures in a comprehensive manner with the help of graphical and pictorial representation which embodies more clarity on the market.

You can buy this complete report @ https://dataintelo.com/checkout/?reportId=80796

Report Covers Impacts of COVID-19 to the market.

The on-going pandemic has overhauled various facets of the market. This research report provides the financial impacts and market disturbance on the Immunology market. It also includes analysis on the potential lucrative opportunities and challenges in the foreseeable future. DataIntelo has interviewed various delegates of the industry and got involved in the primary and secondary research to confer the clients with information and strategies to fight against the market challenges amidst and after COVID-19 pandemic.

Market Segmentation:

Few of the companies that are covered in the report.

AbbVieAmgenF. Hoffmann-La RocheJohnson & JohnsonBionor PharmaCelgeneCellectar BioscienceseFFECTOR Therapeutics

Note: Additional companies can be included in the list upon the request.

By Product Type:

Immuno BoostersImmunosuppressants

By Applications:

Autoimmune DiseasesOncologyOrgan TransplantationOthers

By Geographical Location:Asia Pacific: China, Japan, India, and Rest of Asia PacificEurope: Germany, the UK, France, and Rest of EuropeNorth America: The US, Mexico, and CanadaLatin America: Brazil and Rest of Latin AmericaMiddle East & Africa: GCC Countries and Rest of Middle East & Africa

Get A Free Sample Report @ https://dataintelo.com/request-sample/?reportId=80796

The research report provides a detailed analysis of the prominent player in the market, products, applications, and regional analysis which also include impacts of government policies in the market. Moreover, you can sign up for the yearly updates on the Immunology market.

7 Reasons for Buying Immunology Market Report

If you have any query regarding the report, ask our experts: @ https://dataintelo.com/enquiry-before-buying/?reportId=80796

Below is the TOC of the report:

Immunology Supply Chain Analysis

Immunology Pricing Analysis

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473Email: [emailprotected]Website: https://dataintelo.com

Original post:
Immunology Market ? What Factors Will Drive The Market In Upcoming Years And How It Is Going To Impact On Global Industry | (2020-2026) - The Daily...

Rheos Medicines to Participate in Stifel 2020 Immunology and Inflammation Virtual Summit – Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe immune-mediated diseases, will participate in the upcoming Immunology and Inflammation Virtual Summit hosted by Stifel. Dr. Edward Driggers, Rheoss Chief Technology Officer, will participate in a panel discussion entitled The Key To Unlocking Immune Cell Function at 2:00 PM EDT on Thursday, October 1st, 2020.

A live webcast of the event will be available here: https://wsw.com/webcast/stifel23/panel6/2330952.

About Rheos Medicines

Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop novel therapeutics for patients with severe immune-mediated diseases. Our approach targets the underlying intracellular metabolism of immune cells and has the potential to unlock a new frontier in drug discovery for immune-mediated disease. Through a proprietary platform and product engine that integrates multiple omic datasets, we systematically define the biologic links between immune cell metabolism and function and simultaneously identify new drug targets and biomarkers of disease to bring precision to the treatment of immune-mediated diseases. We have assembled leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team. Rheos was founded by Third Rock Ventures and is located in Cambridge, MA. For more information, please visit http://www.rheosrx.com.

Continued here:
Rheos Medicines to Participate in Stifel 2020 Immunology and Inflammation Virtual Summit - Business Wire

Sanofi’s Dupixent focus will pay off to the tune of $12.5B in peak sales: analysts – FiercePharma

Since taking over at Sanofi a year ago, CEO Paul Hudson has made immunology blockbuster Dupixent one of his top prioritiesand set some lofty sales goals, too.

The company's focus on the drug is already paying off. In fact, it's set to reach $12.5 billion in peak sales, Jefferies analysts wrote, or about 10.8 billion, beating Hudson's own 10 billion goal.

As of the second quarter, Dupixent is generating about $1 billion every three months. Looking forward, Jefferies figures the med can grow based on further penetration into the atopic dermatitis marketwhere its a market leaderand by posting gains in asthma and numerous other indications, the analysts wrote in a Tuesday note to clients.

Developing COVID-19 vaccines may not be enough: Turning vaccines into vaccinations

COVID-19 vaccines are being developed at a breakneck pace, but a broken supply chain could derail that momentum. What are the steps needed to help ensure the medical supply chain is up to the task?

In atopic dermatitis, the Jefferies analysts predict the meds sales could almost double from 3 billion to nearly 6 billion in 2028. That expectation is based on a survey of 25 dermatologists in the U.S., who expect more patients to get treatment over the coming three years.

RELATED: Dupixent sales of 10B? We're on track, Sanofi CEO Hudson says

In asthma, the analysts predict Dupixents sales of around 460 million now will reach 2.9 billion by 2028, based on an assumption that 30% of eligible patients will be treated with a biologic. Meanwhile, Dupixent is already approved in chronic rhinosinusitis with nasal polyps, and the med is in late-stage testing for several other diseases. The analysts predict 2.2 billion in peak sales from uses other than asthma and atopic dermatitis.

Altogether, the analysts expect 10.8 billion in peak sales from Dupixent, above consensus estimates of 9.7 billion.

After taking the reins at Sanofi last September, Hudson said new indications and launches in new countries could fuel Dupixent to more than 10 billion in peak sales. Aside from his focus on Dupixent, Hudson launched a cost-cutting initiative aimed at saving 2 billion by 2022.

RELATED: Sanofi touts Dupixent's pandemic 'resilience' as cost cuts add up

Further, the drugmaker set out to focus its R&D engine only on first-in-class" or best-in-class" drugs, as Hudson puts it. As Sanofi works to advance internal research, the company has been busy scouting and striking deals, recently with its $3.7 billion Principia Biopharma buyout.

While Dupixent will be the company's "key growth driver" moving forward, Jefferies analysts are also optimistic about the company's flu vaccines, its pipeline and its ability to cut costs. From an investment standpoint, they see Sanofi as the most compelling European large pharma company right now.

Link:
Sanofi's Dupixent focus will pay off to the tune of $12.5B in peak sales: analysts - FiercePharma

UGA leads study on COVID-19 post-infection immunity – The Albany Herald

ATHENS A key question surrounding COVID-19 is if people who have had the virus gain some degree of long-term immunity. Ted Ross is leading a nationwide study to examine this pressing question. Ross is director of the University of Georgias Center for Vaccines and Immunology and professor of infectious diseases in the College of Veterinary Medicine.

The bodys response to every infection is unique, Ross said. In this study, we hope to determine how the body fights this novel virus and what, if any, protection the body develops following infection.

The team also hopes to examine immunological, demographic and medical risk factors and the part they play in recovery and infection outcome. Using blood draws and saliva samples, the researchers will monitor participants over the course of 24 months. The project, called SPARTA (SARS SeroPrevalence and Respiratory Tract Assessment), is funded by the NIH National Institute of Allergy and Infectious Diseases and the National Cancer Institute.

In Athens and Augusta, the study will establish and follow participants at higher risk of exposure to the SARS-CoV-2 virus, including local health care and emergency services providers, as well as faculty, staff and students at UGA. The group will total about 3,000 participants between 18 and 85 years of age and at least 50% of the participants will be members of minority populations, which have been impacted by COVID-19 at a higher rate than other groups.

UGA will participate with other teams of investigators from universities and health care providers around the country including Augusta University Medical Center, Mt. Sinai Medical Center in New York City, University of Chicago, University of Miami, University of Michigan at Ann Arbor, University of California at Los Angeles Harbor Medical Center, Washington University Medical Center in St. Louis, and St. Jude Childrens Research Hospital in Memphis.

The list is expected to grow as more institutions join the project. The data collected from these locations will be aggregated and compared for a nationwide view of immunity and recovery from COVID-19.

Follow this link:
UGA leads study on COVID-19 post-infection immunity - The Albany Herald

FlowMetric Life Sciences, Inc. and Penn State University announce a Collaboration Study on University and Community COVID-19 Antibody Testing -…

DOYLESTOWN, Pa., Sept. 29, 2020 /PRNewswire/ --FlowMetric Life Sciences, Inc., a global leader in immunology testing services, and the Huck Institutes of the Life Sciences at Penn State University announce the creation of a long-term collaboration study assessing the impact on the Centre County community's potential exposure to COVID-19 by Penn State University students returning to campus.

Together with Penn State's Center for Clinical Research, the Huck Institutes will collect thousands of blood samples from Penn State students and members of the Centre County community at the beginning and end of each academic semester for four academic semesters.

The samples will be sent to FlowMetric, a GLP-compliant, CLIA-certified, High Complexity clinical laboratory located in Doylestown, PA for analysis. FlowMetric is providing validated serology testing under the FDA's Emergency Use Authorization mandate. The test detects the presence of anti-SARS-CoV-2 (COVID-19) IgG antibodies and will identify individuals who have mounted an immune response following viral exposure, even if they are asymptomatic.

Andrew Read, the project leader with Huck Institutes, said "COVID is a serious challenge that needs local and global focus. We are absolutely delighted to to be partnering with a dynamic and forward-looking Pennsylvanian biotech company on this study. We call it 'Data 4 Action' because we want to make a difference. It is clear that FlowMetric does too".

"This project is a natural extension to the FlowMetric vision of improving the lives of individuals through our cutting-edge science and expertise in immune monitoring" said Renold Capocasale, CEO & Founder of FlowMetric Life Sciences. "We are honored to be partnering with Penn State University, a world-renown center of research excellence" he added.

The results of the study will be reported to the PA Department of Health as part of ongoing surveillance in response to the COVID-19 pandemic. Researchers at Penn State's Institute for Social Sciences will also be collecting questionnaire data on other impacts of COVID including economic and other health impacts. Here is a link to the study site: https://covid-19.ssri.psu.edu/data4action.

About FlowMetric Life Sciences, Inc.With laboratories in Doylestown, PA (USA) and Bresso, Italy, FlowMetric Life Sciences is a globally recognized Contract Research Organization providing World-Class Analytical services, Flow Cytometry and Single-Cell Proteomics capabilities, and expertise in Immunology, Cellular and Gene Therapy, Oncology, and Infectious Diseases, supporting many of the world's largest Pharmaceutical and Biotech companies.

About the Huck Institutes of the Life Sciences at Penn State UniversityThe Huck Institutes were established in 1996 to enhance and facilitate excellence in interdisciplinary research and training in the life sciences across Penn State. We facilitate new initiatives and insights by seeding emerging fields and providing leadership in interdisciplinary graduate education.

SOURCE FlowMetric

flowmetric.com

View original post here:
FlowMetric Life Sciences, Inc. and Penn State University announce a Collaboration Study on University and Community COVID-19 Antibody Testing -...